Renadyl (Kibow Biotech) in study for Kidney Failure patients

Interim data from an expanded clinical trial of Renadyl, a probiotic dietary supplement from Kibow Biotech, confirms positive results for safety and quality of life previously established in a pilot-scale study for Kidney Failure patients. The probiotic microbial strains in the product formulation are "Generally Recognized As Safe" as per US FDA regulations. Renadyl, originally marketed under the name of Kibow Biotics, is a probiotic dietary supplement which is currently being tested to determine its ability to help reduce the build-up of uremic toxins, and thus help maintain healthy kidney function. Following-up on the encouraging results obtained in a multisite, pilot-scale study with Chronic Kidney Disease Stage III and IV patients, an expanded study involves administering the probiotic at higher dosage levels to both predialysis and dialysis patients. These trials, which began in April 2011, are being performed at Thomas Jefferson University, Philadelphia, PA, Downstate Medical Center (State University of New York) and at Kings County Hospital in Brooklyn, NY.